We also proved able to induce disruption of RUNX1-RUNX1T1 in AML t(8;21) patient-derived cells showing the feasibility of CRISPR-Cas9-mediated gene editing of primary leukemic cells. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.